Merck Enters into a Clinical Collaboration with Hookipa to Evaluate Keytruda (pembrolizumab) + HB-200 as 1L Treatment of Advanced Head and Neck Cancers
Shots:
- The companies collaborated to evaluate Hookipa’s HB-200 (arenaviral immunotherapeutic) + Merck’s Keytruda (anti-PD-1 therapy) in a P-II trial for patients with advanced HNSCC- based on an ongoing P-I/II trial of HB-200 for advanced HPV16+ cancers patients
- HB-201 monothx. showed an ORR (18%)- m-PFS (3.45mos.) in heavily pretreated head & neck cancer patients. Preliminary data on HB-201/HB-202 therapy showed a DCR (100%) & P-I data of HB-201 demonstrated a favorable safety profile
- Hookipa is expected to start the P-II trial of HB-200 + Keytruda in 2022 with an anticipated result in Q4’21. Additionally- the company is also expected to initiate P-II expansion cohorts in Q1’22
Ref: Globenewswire | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
